251 related articles for article (PubMed ID: 19690820)
21. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly.
Starner CI; Norman SA; Reynolds RG; Gleason PP
Am J Geriatr Pharmacother; 2009 Feb; 7(1):11-9. PubMed ID: 19281936
[TBL] [Abstract][Full Text] [Related]
22. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
23. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
[TBL] [Abstract][Full Text] [Related]
24. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.
Evans-Molina C; Regan S; Henault LE; Hylek EM; Schwartz GR
J Am Geriatr Soc; 2007 Jul; 55(7):1038-43. PubMed ID: 17608876
[TBL] [Abstract][Full Text] [Related]
25. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
26. Adverse selection in the Medicare prescription drug program.
Riley GF; Levy JM; Montgomery MA
Health Aff (Millwood); 2009; 28(6):1826-37. PubMed ID: 19887424
[TBL] [Abstract][Full Text] [Related]
27. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
28. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.
Stuart B; Doshi JA; Briesacher B; Wrobel MV; Baysac F
Clin Ther; 2004 Oct; 26(10):1688-99. PubMed ID: 15598486
[TBL] [Abstract][Full Text] [Related]
29. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective.
Lee WC; Lamas GA; Balu S; Spalding J; Wang Q; Pashos CL
J Med Econ; 2008; 11(2):281-98. PubMed ID: 19450086
[TBL] [Abstract][Full Text] [Related]
30. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting.
Hallinen T; Martikainen JA; Soini EJ; Suominen L; Aronkytö T
Curr Med Res Opin; 2006 Apr; 22(4):683-92. PubMed ID: 16684429
[TBL] [Abstract][Full Text] [Related]
31. Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors.
Amin AN; Jhaveri M; Lin J
J Med Econ; 2012; 15(3):548-55. PubMed ID: 22352988
[TBL] [Abstract][Full Text] [Related]
32. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.
Nair KV; Frech-Tamas F; Jan S; Wolfe P; Allen RR; Saseen JJ
J Health Care Finance; 2011; 38(2):38-53. PubMed ID: 22372031
[TBL] [Abstract][Full Text] [Related]
33. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
De Natale ML
Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
[TBL] [Abstract][Full Text] [Related]
34. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
35. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
36. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
37. The economic burden of congestive heart failure in a managed care population.
Xuan J; Duong PT; Russo PA; Lacey MJ; Wong B
Am J Manag Care; 2000 Jun; 6(6):693-700. PubMed ID: 10977478
[TBL] [Abstract][Full Text] [Related]
38. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
39. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation.
Kim MH; Klingman D; Lin J; Battleman DS
Pharmacotherapy; 2009 Dec; 29(12):1417-26. PubMed ID: 19947801
[TBL] [Abstract][Full Text] [Related]
40. The impact of Medicare Part D on prescription drug use by the elderly.
Lichtenberg FR; Sun SX
Health Aff (Millwood); 2007; 26(6):1735-44. PubMed ID: 17978393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
